| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 473,50 | 473,55 | 15:22 | |
| 470,20 | 471,05 | 01.06. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 475,05 | 7 | |||
| 475,00 | 7 | |||
| 474,95 | 39 | |||
| 474,90 | 7 | |||
| 474,85 | 7 | |||
| 474,80 | 80 | |||
| 474,75 | 37 | |||
| 474,70 | 7 | |||
| 474,65 | 40 | |||
| 474,55 | 17 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/moh.htm [/URL] | ||||
| 11 | 474,30 | |||
| 80 | 474,15 | |||
| 7 | 474,10 | |||
| 37 | 474,05 | |||
| 110 | 474,00 | |||
| 37 | 473,95 | |||
| 30 | 473,90 | |||
| 37 | 473,85 | |||
| 110 | 473,80 | |||
| 7 | 473,75 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 466 | 0,532 | 248 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 15:05:51 | 474,30 | 4 |
| 14:59:37 | 474,30 | 10 |
| 14:57:31 | 474,60 | 7 |
| 14:56:58 | 474,65 | 4 |
| 14:56:58 | 474,45 | 10 |
| 14:55:10 | 474,80 | 20 |
| 14:40:49 | 474,95 | 9 |
| 14:35:12 | 475,10 | 4 |
| 14:33:39 | 474,60 | 1 |
| 14:25:04 | 476,15 | 6 |
| 14:21:40 | 476,60 | 17 |
| 14:21:40 | 476,55 | 7 |
| 14:21:40 | 476,50 | 17 |
| 14:21:40 | 476,45 | 7 |
| 14:21:40 | 476,40 | 17 |
| 14:21:40 | 476,35 | 19 |
| 14:21:40 | 476,30 | 10 |
| 14:21:40 | 476,25 | 90 |
| 14:21:40 | 476,15 | 9 |
| 14:21:40 | 476,10 | 7 |
| Tagesumsatz Xetra | +4,80 +1,02 % | 2.057 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:31 | LVMH names former Lancôme executive President of Sephora Collection | - | Cosmetics Business | ||
| 09:37 | Former LVMH boss Anish Melwani on why connection is luxury's most valuable asset | 2 | Inside Retail | ||
| LVMH Aktie jetzt für 0€ handeln | |||||
| 09:31 | LVMH im freien Fall: Was die wenigsten Anleger auf dem Schirm haben - Was ich konkret unternommen habe | Hebelschein-Spekulant | |||
| 09:26 | LVMH MOET HENNESSY LOUIS VUITTON SE: Struktur im Stillen | 5 | Maximilian Berger | ||
| Mo | Loro Piana vertieft erneut Verbundenheit mit Welt des Reitsports | 8 | FashionUnited |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mo | Dividendenbekanntmachungen (01.06.2026) | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCOR SA FR0000120404 - 1,35 EUR ACNB CORPORATION US0008681092 0,92 USD 0,7889 EUR AGNICO EAGLE MINES LIMITED CA0084741085 0,45... ► Artikel lesen | |
| 12:15 | Dividendenbekanntmachungen (02.06.2026) | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEROPORTS DE PARIS SA FR0010340141 - 3,8 EUR AKWEL SA FR0000053027 - 0,3 EUR ALPINE SELECT AG CH0019199550 0,6 CHF 0,6556 EUR ANALOG... ► Artikel lesen | |
| So | Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm | PR Newswire | Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis... ► Artikel lesen | |
| So | J&J Phase 1b/2 OrigAMI-4: Subcutaneous Amivantamab Shows 42% ORR In Head & Neck Cancer | AFX News | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced pivotal results from the Phase 1b/2 OrigAMI-4 study, which evaluated subcutaneous amivantamab with hyaluronidase-lpuj in patients... ► Artikel lesen | |
| So | J&J Phase 3: Apalutamide + Hormone Therapy Before & After Surgery Improves Prostate Cancer Outcomes | AFX News | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy... ► Artikel lesen |